Embecta Corp. (NASDAQ:EMBC) Given Consensus Recommendation of “Reduce” by Brokerages

Shares of Embecta Corp. (NASDAQ:EMBC) have earned a consensus rating of “Reduce” from the five research firms that are presently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation and three have assigned a hold recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $11.00.

Several research firms recently weighed in on EMBC. Mizuho reduced their target price on Embecta from $12.00 to $5.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. Wall Street Zen cut Embecta from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. BTIG Research downgraded shares of Embecta from a “buy” rating to a “neutral” rating in a research note on Tuesday, May 5th. Zacks Research upgraded shares of Embecta from a “strong sell” rating to a “hold” rating in a report on Friday, July 17th. Finally, Weiss Ratings cut shares of Embecta from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, August 3rd.

Insider Buying and Selling at Embecta

In other news, CEO Devdatt Kurdikar acquired 30,000 shares of the company’s stock in a transaction dated Wednesday, August 12th. The stock was acquired at an average cost of $4.70 per share, for a total transaction of $141,000.00. Following the acquisition, the chief executive officer directly owned 804,919 shares in the company, valued at approximately $3,783,119.30. This represents a 3.87% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Jacob Elguicze acquired 20,000 shares of the company’s stock in a transaction dated Wednesday, August 12th. The shares were purchased at an average price of $4.67 per share, with a total value of $93,400.00. Following the completion of the acquisition, the chief financial officer owned 309,139 shares in the company, valued at approximately $1,443,679.13. The trade was a 6.92% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 70,000 shares of company stock worth $334,200 in the last quarter. 1.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Embecta

A number of institutional investors have recently added to or reduced their stakes in the company. Larson Financial Group LLC raised its holdings in shares of Embecta by 368.6% in the 3rd quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock worth $28,000 after purchasing an additional 1,574 shares during the period. One Wealth Advisors LLC acquired a new position in shares of Embecta in the 2nd quarter valued at about $33,000. Tower Research Capital LLC TRC grew its holdings in shares of Embecta by 542.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company’s stock worth $71,000 after purchasing an additional 6,224 shares during the period. Wexford Capital LP purchased a new stake in shares of Embecta during the 3rd quarter worth about $94,000. Finally, Humankind Investments LLC acquired a new stake in Embecta during the 2nd quarter worth approximately $111,000. Hedge funds and other institutional investors own 93.83% of the company’s stock.

Embecta Stock Performance

Shares of EMBC opened at $5.03 on Wednesday. The stock has a fifty day moving average of $3.78 and a two-hundred day moving average of $6.11. The company has a market capitalization of $285.00 million, a PE ratio of 3.40 and a beta of 0.81. Embecta has a fifty-two week low of $2.77 and a fifty-two week high of $15.55.

Embecta (NASDAQ:EMBC) last posted its quarterly earnings data on Friday, August 7th. The company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.29. The business had revenue of $271.70 million for the quarter, compared to analysts’ expectations of $254.53 million. Embecta had a negative return on equity of 19.25% and a net margin of 8.59%.The business’s revenue was down 8.1% on a year-over-year basis. During the same quarter last year, the firm earned $1.12 earnings per share. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. As a group, equities research analysts forecast that Embecta will post 1.84 earnings per share for the current fiscal year.

Embecta Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Thursday, August 27th will be paid a dividend of $0.01 per share. The ex-dividend date of this dividend is Thursday, August 27th. This represents a $0.04 dividend on an annualized basis and a yield of 0.8%. Embecta’s dividend payout ratio (DPR) is currently 2.70%.

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.